Menu

COVID-19 Frontline Initiative: Supporting Patient Journeys through Resources and Tools to Promote Positive Patient Outcomes in Care

When:
June 27, 2020 @ 2:53 pm – June 28, 2022 @ 3:53 pm
2020-06-27T14:53:00+00:00
2022-06-28T15:53:00+00:00

COVID-19 Frontline Initiative:
Supporting Patient Journeys through Resources and Tools to Promote Positive Patient Outcomes in Care

Download Toolkit

Patient Journey e-booklet

MOA Animation

Patient Antibodies Animation

View Activity

PROGRAM OVERVIEW

COVID-19 FRONTLINE podcasts provide a comprehensive and up-to-date perspective on the ever-changing management and prevention of COVID-19. Each podcast focuses on different issues facing clinicians and patients, such as managing patients with COVID-19, addressing the care of special populations during the pandemic, and coping with the long road to recovery.


TARGET AUDIENCE

The innovative continuing education and tools developed for FRONTLINE will be publicly available for the entire health care community to use. Participants will come from a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other health care professionals to help support them in their effort to optimize care of patients with COVID-19.


LEARNING OBJECTIVES

On completing this program, attendees should be able to:

  • Recognize the importance of Continuity of Care for non-COVID positive patients during the COVID-19 pandemic

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, MPH, Accreditation and Outcomes Coordinator, has nothing to disclose.
Melissa A Johnson, Senior Program Manager for Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.


METHOD OF PARTICIPATION

There are no fees for participating for this online activity.


DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making experience before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected].

RELEASE DATE: May 28, 2021

EXPIRATION DATE: May 28, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITY ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill